Currently, there are 45.58M common shares owned by the public and among those 40.12M shares have been available to trade.
The company’s stock has a 5-day price change of -41.88% and -51.56% over the past three months. CAPR shares are trading -47.10% year to date (YTD), with the 12-month market performance up to 39.31% higher. It has a 12-month low price of $3.52 and touched a high of $23.40 over the same period. CAPR has an average intraday trading volume of 1.44 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -34.22%, -38.74%, and -41.09% respectively.
Institutional ownership of Capricor Therapeutics Inc (NASDAQ: CAPR) shares accounts for 38.76% of the company’s 45.58M shares outstanding.
It has a market capitalization of $333.44M and a beta (3y monthly) value of 0.97. The earnings-per-share (ttm) stands at -$1.20. Price movements for the stock have been influenced by the stock’s volatility, which stands at 17.39% over the week and 11.38% over the month.
Earnings per share for the fiscal year are expected to increase by 66.96%, and 116.54% over the next financial year.
Looking at the support for the CAPR, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on October 21, 2024, with the firm’s price target at $35. Oppenheimer coverage for the Capricor Therapeutics Inc (CAPR) stock in a research note released on May 17, 2024 offered a Outperform rating with a price target of $14. Cantor Fitzgerald was of a view on January 05, 2024 that the stock is Overweight, while Ladenburg Thalmann gave the stock Buy rating on October 26, 2022, issuing a price target of $15. Maxim Group on their part issued Hold rating on December 26, 2018.
